---
title: "Immutep Secures Dr. Reddy’s Partnership and Strengthens Clinical, Financial Position"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274084603.md"
description: "Immutep Ltd has secured a partnership with Dr. Reddy’s for the commercialization of eftilagimod alfa, receiving an upfront payment of approximately A$30 million and potential milestones of up to A$528 million. The company reported strong clinical progress, including positive trial results and a pro-forma cash balance of A$129.3 million, enhancing its financial position in the oncology sector. The latest analyst rating for Immutep (AU:IMM) is a Hold with a price target of A$0.46."
datetime: "2026-01-29T03:28:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274084603.md)
  - [en](https://longbridge.com/en/news/274084603.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274084603.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274084603.md) | [English](https://longbridge.com/en/news/274084603.md)


# Immutep Secures Dr. Reddy’s Partnership and Strengthens Clinical, Financial Position

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Immutep Ltd ( (AU:IMM) ) has provided an update.

Immutep reported a pivotal quarter marked by a strategic licensing and collaboration deal with Dr. Reddy’s for the commercialisation of eftilagimod alfa in most ex-U.S./EU markets, delivering an upfront payment of about A$30 million and access to up to roughly A$528 million in potential milestones plus royalties, while Immutep retains key-market rights and global manufacturing. The company highlighted strong clinical and regulatory momentum for efti, including robust enrolment and an upcoming futility analysis in the Phase III TACTI-004 lung cancer trial, positive Phase I/II data in first-line non-small cell lung cancer and soft tissue sarcoma, confirmation from the U.S. FDA of a 30 mg optimal biological dose, and encouraging immunosuppressive signals from IMP761 in Phase I; together with a pro-forma cash balance of about A$129.3 million and a French R&D tax incentive, these developments significantly extend Immutep’s cash runway and strengthen its positioning in the competitive oncology and autoimmune immunotherapy landscape.

The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

**More about Immutep Ltd**

Immutep Limited is a late-stage immunotherapy company focused on developing treatments for cancer and autoimmune diseases, led by its first-in-class antigen-presenting cell activator eftilagimod alfa (efti) and its LAG-3 agonist antibody IMP761. The company is advancing multiple global clinical programs in lung, breast and soft tissue sarcoma cancers while retaining manufacturing rights to efti worldwide and core commercial rights in major markets such as North America, Europe and Japan.

**Average Trading Volume:** 3,752,497

**Technical Sentiment Signal:** Buy

**Current Market Cap:** A$677.9M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.

### 相關股票

- [Immutep (IMMP.US)](https://longbridge.com/zh-HK/quote/IMMP.US.md)
- [Dr Reddys Laboratories (RDY.US)](https://longbridge.com/zh-HK/quote/RDY.US.md)

## 相關資訊與研究

- [Immutep halts late-stage trial for lead asset after efficacy analysis](https://longbridge.com/zh-HK/news/279032924.md)
- [Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial](https://longbridge.com/zh-HK/news/279076056.md)
- [Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Drops](https://longbridge.com/zh-HK/news/279000682.md)
- [Dr Reddy's says IDMC recommends discontinuation of TACTI-004 phase III trial after interim futility analysis](https://longbridge.com/zh-HK/news/279051782.md)
- [Immutep crashes 90% as Phase III lung cancer trial discontinued](https://longbridge.com/zh-HK/news/278986601.md)